Physician profile
Elise E Murray
NPI 1386746725
$5,395.28
in general payments reported to CMS, 2019-2025
37 companies · $1,007 in 2025
The $1,007 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $674 · 2020: $649 · 2021: $954 · 2022: $707 · 2023: $767 · 2024: $637 · 2025: $1,007.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,410.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $753.29 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $629.53 | 2019-2024 | Jardiance, Tradjenta, Spiriva Respimat |
| Abbvie INC. | $529.97 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $466.58 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Janssen Pharmaceuticals, INC | $451.84 | 2019-2025 | Xarelto, Spravato |
| Lilly USA, LLC | $441.12 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $314.83 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $283.85 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $188.35 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $150.88 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $134.36 | 2019-2025 | Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $113.53 | 2025 | |
| Lundbeck LLC | $106.91 | 2024-2025 | Rexulti |
| Dexcom, INC. | $99.14 | 2021-2024 | Dexcom G6 Transmitter |
| Alkermes, INC. | $88.60 | 2025 | Aristada, Lybalvi |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elise Murray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.